{"id":12525,"date":"2021-05-19T14:51:12","date_gmt":"2021-05-19T13:51:12","guid":{"rendered":"https:\/\/ppr-antibioresistance.inserm.fr\/?p=11449"},"modified":"2021-05-20T16:04:46","modified_gmt":"2021-05-20T15:04:46","slug":"novartis-consacre-150-me-a-la-fabrication-dantibiotiques","status":"publish","type":"post","link":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/novartis-consacre-150-me-a-la-fabrication-dantibiotiques\/","title":{"rendered":"Novartis : consacre 150 ME \u00e0 la fabrication d&#8217;antibiotiques"},"content":{"rendered":"\n<p>Article publi\u00e9 sur <a href=\"https:\/\/www.zonebourse.com\/cours\/action\/NOVARTIS-AG-9364983\/actualite\/Novartis-nbsp-consacre-150-ME-a-la-fabrication-d-antibiotiques-33286765\/\" target=\"_blank\" rel=\"noreferrer noopener\">Zonebourse.com<\/a>, 18\/05\/2021, 11:16<\/p>\n\n\n\n<p>Sandoz, une division de Novartis, annonce aujourd&#8217;hui son intention de renforcer davantage son r\u00e9seau europ\u00e9en de fabrication d&#8217;antibiotiques en \u00e9tendant ses capacit\u00e9s de production \u00e0 Kundl (Autriche) et \u00e0 Palafolls (Espagne).<\/p>\n\n\n\n<p>Sandoz confirme ainsi un investissement de plus de 100 ME en Autriche afin d&#8217;introduire une nouvelle technologie de fabrication pour la production d&#8217;amoxicilline orale, un ingr\u00e9dient pharmaceutique actif (API) pour son principal produit de p\u00e9nicilline<\/p>\n\n\n\n<p>Par ailleurs, dans le cadre de l&#8217;expansion du site de Palafolls, Sandoz pr\u00e9voit d&#8217;investir 50 millions d&#8217;euros dans une nouvelle technologie de production et une capacit\u00e9 accrue pour la production d&#8217;API de p\u00e9nicilline st\u00e9riles et de m\u00e9langes d&#8217;API st\u00e9riles.<\/p>\n\n\n\n<p>Les antibiotiques sont consid\u00e9r\u00e9s comme &#8216;l&#8217;\u00e9pine dorsale des soins de sant\u00e9 modernes et un pilier strat\u00e9gique cl\u00e9 de l&#8217;entreprise&#8217;, indique le PDG de Sandoz, Richard Saynor.<\/p>\n\n\n\n<p>&#8216;Les investissements importants annonc\u00e9s aujourd&#8217;hui permettront \u00e0 notre r\u00e9seau de fabrication de classe mondiale en Europe de r\u00e9pondre aux besoins futurs &#8216;, ajoute Giovanni Barbella, responsable des op\u00e9rations techniques de Sandoz.<\/p>\n\n\n\n<p><a href=\"http:\/\/www.facebook.com\/sharer.php?u=http:\/\/www.zonebourse.com\/cours\/action\/NOVARTIS-AG-9364983\/actualite\/Novartis-nbsp-consacre-150-ME-a-la-fabrication-d-antibiotiques-33286765\/?utm_campaign=promo+202102+share_article++fr_fr&amp;utm_source=facebook&amp;utm_medium=display\"><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Article publi\u00e9 sur Zonebourse.com, 18\/05\/2021, 11:16 Sandoz, une division de Novartis, annonce aujourd&#8217;hui son intention de renforcer davantage son r\u00e9seau europ\u00e9en de fabrication d&#8217;antibiotiques en \u00e9tendant ses capacit\u00e9s de production \u00e0 Kundl (Autriche) et \u00e0 Palafolls (Espagne). Sandoz confirme ainsi un investissement de plus de 100 ME en Autriche afin d&#8217;introduire une nouvelle technologie de [&hellip;]<\/p>\n","protected":false},"author":139,"featured_media":11451,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[31],"tags":[],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.8 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Novartis : consacre 150 ME \u00e0 la fabrication d&#039;antibiotiques - French\u00a0National ANTIBIOTIC RESISTANCE Portal<\/title>\n<meta name=\"description\" content=\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l&#039;Antibior\u00e9sistance en France et \u00e0 l&#039;international.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/novartis-consacre-150-me-a-la-fabrication-dantibiotiques\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novartis : consacre 150 ME \u00e0 la fabrication d&#039;antibiotiques - French\u00a0National ANTIBIOTIC RESISTANCE Portal\" \/>\n<meta property=\"og:description\" content=\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l&#039;Antibior\u00e9sistance en France et \u00e0 l&#039;international.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/novartis-consacre-150-me-a-la-fabrication-dantibiotiques\/\" \/>\n<meta property=\"og:site_name\" content=\"French\u00a0National ANTIBIOTIC RESISTANCE Portal\" \/>\n<meta property=\"article:published_time\" content=\"2021-05-19T13:51:12+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-05-20T15:04:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/05\/Antibiotiques-gelules.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"852\" \/>\n\t<meta property=\"og:image:height\" content=\"509\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"\u00c9milie Noguez\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"\u00c9milie Noguez\" \/>\n\t<meta name=\"twitter:label2\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/novartis-consacre-150-me-a-la-fabrication-dantibiotiques\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/novartis-consacre-150-me-a-la-fabrication-dantibiotiques\/\"},\"author\":{\"name\":\"\u00c9milie Noguez\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3\"},\"headline\":\"Novartis : consacre 150 ME \u00e0 la fabrication d&#8217;antibiotiques\",\"datePublished\":\"2021-05-19T13:51:12+00:00\",\"dateModified\":\"2021-05-20T15:04:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/novartis-consacre-150-me-a-la-fabrication-dantibiotiques\/\"},\"wordCount\":186,\"publisher\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/novartis-consacre-150-me-a-la-fabrication-dantibiotiques\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/05\/Antibiotiques-gelules.jpg\",\"articleSection\":[\"Actualit\u00e9s\"],\"inLanguage\":\"en-GB\"},{\"@type\":[\"WebPage\",\"ItemPage\"],\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/novartis-consacre-150-me-a-la-fabrication-dantibiotiques\/\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/novartis-consacre-150-me-a-la-fabrication-dantibiotiques\/\",\"name\":\"Novartis : consacre 150 ME \u00e0 la fabrication d'antibiotiques - French\u00a0National ANTIBIOTIC RESISTANCE Portal\",\"isPartOf\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/novartis-consacre-150-me-a-la-fabrication-dantibiotiques\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/novartis-consacre-150-me-a-la-fabrication-dantibiotiques\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/05\/Antibiotiques-gelules.jpg\",\"datePublished\":\"2021-05-19T13:51:12+00:00\",\"dateModified\":\"2021-05-20T15:04:46+00:00\",\"description\":\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.\",\"breadcrumb\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/novartis-consacre-150-me-a-la-fabrication-dantibiotiques\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/novartis-consacre-150-me-a-la-fabrication-dantibiotiques\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/novartis-consacre-150-me-a-la-fabrication-dantibiotiques\/#primaryimage\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/05\/Antibiotiques-gelules.jpg\",\"contentUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/05\/Antibiotiques-gelules.jpg\",\"width\":852,\"height\":509,\"caption\":\"Cr\u00e9dit : Pixabay\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/novartis-consacre-150-me-a-la-fabrication-dantibiotiques\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Practical info &amp; communications\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"News\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/news\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Novartis : consacre 150 ME \u00e0 la fabrication d&#8217;antibiotiques\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#website\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/\",\"name\":\"French\u00a0National ANTIBIOTIC RESISTANCE Portal\",\"description\":\"INSERM - From science to health\",\"publisher\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization\",\"name\":\"Inserm\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg\",\"contentUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg\",\"width\":1,\"height\":1,\"caption\":\"Inserm\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3\",\"name\":\"\u00c9milie Noguez\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Novartis : consacre 150 ME \u00e0 la fabrication d'antibiotiques - French\u00a0National ANTIBIOTIC RESISTANCE Portal","description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/novartis-consacre-150-me-a-la-fabrication-dantibiotiques\/","og_locale":"en_GB","og_type":"article","og_title":"Novartis : consacre 150 ME \u00e0 la fabrication d'antibiotiques - French\u00a0National ANTIBIOTIC RESISTANCE Portal","og_description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","og_url":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/novartis-consacre-150-me-a-la-fabrication-dantibiotiques\/","og_site_name":"French\u00a0National ANTIBIOTIC RESISTANCE Portal","article_published_time":"2021-05-19T13:51:12+00:00","article_modified_time":"2021-05-20T15:04:46+00:00","og_image":[{"width":852,"height":509,"url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/05\/Antibiotiques-gelules.jpg","type":"image\/jpeg"}],"author":"\u00c9milie Noguez","twitter_card":"summary_large_image","twitter_misc":{"Written by":"\u00c9milie Noguez","Estimated reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/novartis-consacre-150-me-a-la-fabrication-dantibiotiques\/#article","isPartOf":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/novartis-consacre-150-me-a-la-fabrication-dantibiotiques\/"},"author":{"name":"\u00c9milie Noguez","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3"},"headline":"Novartis : consacre 150 ME \u00e0 la fabrication d&#8217;antibiotiques","datePublished":"2021-05-19T13:51:12+00:00","dateModified":"2021-05-20T15:04:46+00:00","mainEntityOfPage":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/novartis-consacre-150-me-a-la-fabrication-dantibiotiques\/"},"wordCount":186,"publisher":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/novartis-consacre-150-me-a-la-fabrication-dantibiotiques\/#primaryimage"},"thumbnailUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/05\/Antibiotiques-gelules.jpg","articleSection":["Actualit\u00e9s"],"inLanguage":"en-GB"},{"@type":["WebPage","ItemPage"],"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/novartis-consacre-150-me-a-la-fabrication-dantibiotiques\/","url":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/novartis-consacre-150-me-a-la-fabrication-dantibiotiques\/","name":"Novartis : consacre 150 ME \u00e0 la fabrication d'antibiotiques - French\u00a0National ANTIBIOTIC RESISTANCE Portal","isPartOf":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/novartis-consacre-150-me-a-la-fabrication-dantibiotiques\/#primaryimage"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/novartis-consacre-150-me-a-la-fabrication-dantibiotiques\/#primaryimage"},"thumbnailUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/05\/Antibiotiques-gelules.jpg","datePublished":"2021-05-19T13:51:12+00:00","dateModified":"2021-05-20T15:04:46+00:00","description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","breadcrumb":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/novartis-consacre-150-me-a-la-fabrication-dantibiotiques\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/novartis-consacre-150-me-a-la-fabrication-dantibiotiques\/"]}]},{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/novartis-consacre-150-me-a-la-fabrication-dantibiotiques\/#primaryimage","url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/05\/Antibiotiques-gelules.jpg","contentUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/05\/Antibiotiques-gelules.jpg","width":852,"height":509,"caption":"Cr\u00e9dit : Pixabay"},{"@type":"BreadcrumbList","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/novartis-consacre-150-me-a-la-fabrication-dantibiotiques\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/"},{"@type":"ListItem","position":2,"name":"Practical info &amp; communications","item":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/"},{"@type":"ListItem","position":3,"name":"News","item":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/news\/"},{"@type":"ListItem","position":4,"name":"Novartis : consacre 150 ME \u00e0 la fabrication d&#8217;antibiotiques"}]},{"@type":"WebSite","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#website","url":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/","name":"French\u00a0National ANTIBIOTIC RESISTANCE Portal","description":"INSERM - From science to health","publisher":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-GB"},{"@type":"Organization","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization","name":"Inserm","url":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/logo\/image\/","url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg","contentUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg","width":1,"height":1,"caption":"Inserm"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3","name":"\u00c9milie Noguez"}]}},"publishpress_future_action":{"enabled":false,"date":"2026-05-07 08:49:50","action":"change-status","newStatus":"private","terms":[],"taxonomy":"category"},"post_mailing_queue_ids":[],"_links":{"self":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/posts\/12525"}],"collection":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/users\/139"}],"replies":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/comments?post=12525"}],"version-history":[{"count":1,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/posts\/12525\/revisions"}],"predecessor-version":[{"id":12571,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/posts\/12525\/revisions\/12571"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/media\/11451"}],"wp:attachment":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/media?parent=12525"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/categories?post=12525"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/tags?post=12525"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}